Daily Stock Analysis, AEZS, AEterna Zentaris Inc, priceseries

AEterna Zentaris Inc. Daily Stock Analysis
Stock Information
Open
0.81
Close
0.80
High
0.83
Low
0.80
Previous Close
0.81
Daily Price Gain
-0.01
YTD High
5.57
YTD High Date
Apr 5, 2019
YTD Low
0.80
YTD Low Date
Dec 12, 2019
YTD Price Change
-2.23
YTD Gain
-73.59%
52 Week High
5.57
52 Week High Date
Apr 5, 2019
52 Week Low
0.80
52 Week Low Date
Dec 12, 2019
52 Week Price Change
-2.05
52 Week Gain
-71.92%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 9. 2017
2.95
Feb 21. 2017
3.19
7 Trading Days
8.02%
Link
LONG
May 25. 2017
0.96
Jun 12. 2017
1.06
11 Trading Days
10.04%
Link
LONG
Jul 19. 2017
2.34
Jul 24. 2017
2.54
3 Trading Days
8.33%
Link
LONG
May 23. 2018
1.94
Jun 5. 2018
2.16
8 Trading Days
11.38%
Link
LONG
Nov 8. 2018
2.13
Nov 23. 2018
2.61
10 Trading Days
22.53%
Link
LONG
Nov 26. 2018
3.00
Dec 11. 2018
3.31
10 Trading Days
10.50%
Link
LONG
Jan 3. 2019
3.08
Jan 18. 2019
3.60
11 Trading Days
16.99%
Link
LONG
Jan 25. 2019
3.63
Feb 13. 2019
3.97
13 Trading Days
9.30%
Link
LONG
Mar 29. 2019
4.65
Apr 11. 2019
4.95
9 Trading Days
6.53%
Link
Company Information
Stock Symbol
AEZS
Exchange
NasdaqCM
Company URL
http://www.aezsinc.com
Company Phone
843-900-3201
CEO
David A. Dodd
Headquarters
Quebec
Business Address
C/O NORTON ROSE FULBRIGHT CANADA LLP, 1 PLACE VILLE MARIE, SUITE 2500, MONTREAL, CANADA H3B 1R1
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001113423
About

Æterna Zentaris, Inc. operates as a specialty biopharmaceutical company that is engaged in developing and commercializing novel treatments in oncology, endocrinology and women's health. The company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. It focuses on the development of Perifosine, Cetrotide, Ozarelix, AEZS-108 and AEZS-130. AEterna Zentaris was founded on September 12, 1990 and is headquartered in Montreal, Canada.

Description

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. The company's product pipeline includes Zoptrex, which is in Phase III clinical study zoptarelin doxorubicin in endometrial cancer (ZoptEC) of the compound in women with advanced, recurrent, or metastatic endometrial cancer, as well as completed Phase II clinical trial for the treatment of ovarian and prostate cancer; and MACRILEN, which is in Phase III trial for use in the diagnosis of adult growth hormone deficiency. It is also developing two oncology compounds, including an Erk inhibitor and luteinizing hormone-releasing hormone-disorazol Z product candidates, which are in pre-clinical development; and AEZS-120 for the treatment of prostate cancer. Aeterna Zentaris Inc. was founded in 1991 and is headquartered in Summerville, South Carolina.